Poster Abstract Session:
131. Antimicrobial Agents: PK/PD Studies
Friday, October 9, 2015: 12:30 PM-2:00 PM
Room: Poster Hall

Learning Objectives:

-

Tracks: Adult ID

Presentations:
792
A Pharmacokinetic Validation Study of Once Daily Dosing of Intravenous Gentamicin and Tobramycin in Paediatric Patients
Erin Chung, HonBSc, BScPhm, RPh ; Rachel Xia-Ying Liu, PharmD candidate ; Marina Strzelecki, BScPhm, ACPR, RPh ; Michael Pe, BScPhm, ACPR, RPh ; Laura Wang, BScPhm, ACPR, RPh ; Vicky Papaioannou, MClSc, AUD(C), Reg. CASPLO ; Elizabeth Harvey, MD, FRCPC ; Susan Richardson, MD, FRCPC ; Ari Bitnun, MD, MSc, FRCPC ; Winnie Seto, BScPhm, PharmD, MSc, ACPR, RPh
Posters
  • Erin Chung - Poster 792.pdf (561.8 kB)
  • 793
    Pharmacokinetic-Pharmacodynamic (PK-PD) Target Attainment (TA) Analyses Supporting Lefamulin Dose Selection for the Treatment of Patients with Community-Acquired Bacterial Pneumonia (CABP)
    Sujata M. Bhavnani, PharmD, MS ; Paul G. Ambrose, PharmD, FIDSA ; Wolfgang W. Wicha, M.S. ; Zrinka Ivezic-Schoenfeld, Ph.D. ; William T. Prince, Ph.D., MB, BChir, FFPM ; Christopher M. Rubino, Pharm.D.
    794
    Rationale for Dose Selection for  Carbavance (CVC; Meropenem/RPX7009) in Phase 3 Trials
    Olga Lomovskaya, PhD ; David Griffith, BS ; Jeff Loutit, MBChB ; Michael Dudley, PharmD, FIDSA
    795
    Pharmacokinetic and Pharmacodynamics (PK/PD) of Piperacillin (PIP) in Patients on Intermittent Hemodialysis (HD)
    Harrison Bachmeier, PharmD., BCPS ; Benjamin J. Ereshefsky, PharmD ; David J. Feola, PharmD, PhD ; Craig a. Martin, PharmD ; David S. Burgess, PharmD, FCCP
    796
    Optimizing Beta-Lactam Pharmacodynamics Against Pseudomonas aeruginosa in Adult Cystic Fibrosis Patients
    Robert Z. Thompson, PharmD ; Craig Martin, PharmD ; Donna R. Burgess, RPh ; W. Cliff Rutter, PharmD ; David S. Burgess, PharmD, FCCP
    797
    Single Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of a FabI Inhibitor, the Prodrug Debio 1450 and its Active Moiety Debio 1452, Administered Intravenously in Healthy Subjects
    Barry Hafkin, MD ; Jolene K Berg, MD ; Nachum Kaplan, PhD ; Valérie Nicolas Métral, PhD ; Annick Ménétrey, PhD ; Harry Alcorn Jr., PharmD ; Frederick Wittke, MD
    799
    Improving Vancomycin Dosing in the Pediatric Population
    Michelle Jones, DO ; Rachel Mathews, PharmD ; Michael Bolton, MD
    Posters
  • Slide1.jpg (116.7 kB)
  • 801
    Factors Associated with Supratherapeutic Vancomycin Trough Concentrations in a Referral Center
    W. Cliff Rutter, PharmD ; Jeffrey C. Talbert, PhD ; David S. Burgess, PharmD, FCCP
    Posters
  • Vanc troughs poster final.pdf (565.0 kB)
  • 802
    Optimal Vancomycin Dosing: How Much, How Often?
    Kevin S. Akers, MD, FIDSA ; Krista L. Niece, PhD ; Jason M. Cota, PharmD, MSc ; Kevin K. Chung, MD ; Clinton K. Murray, MD, FIDSA
    804
    Pharmacokinetics of Doxycycline in Extracorporeal Membrane Oxygenation
    Tapan Mehta, M.D. ; Tine Vindenes, M.D. ; Kirthana Beaulac, PharmD ; Russel Roberts, Pharm D
    807
    Population PK/PD Modeling of Human Respiratory Syncytial Virus Infection and the Antiviral Effect of AL-8176
    Kashyap Patel, PhD ; Carl Kirkpatrick, PhD ; Keith Nieforth, PhD ; Sushmita Chanda, PhD ; Qingling Zhang, PhD ; Matthew Mcclure, MD ; John Fry, RN ; Julian Symons, D.Phil ; Lawrence Blatt, PhD ; Leo Beigelman, PhD ; Patrick Smith, PharmD
    808
    Comparison of Serum Concentrations between Posaconazole Delayed-release Tablet and Oral Suspension at a Large Academic Medical Center
    Sarah Welch, PharmD ; Andrea Pallotta, PharmD ; Catherine Weber, PharmD ; Caitlin Siebenaller, PharmD ; Eric Cober, MD ; Elizabeth Neuner, PharmD
    Posters
  • Welch_ID Week Posa Poster.pdf (289.9 kB)
  • 810
    Voriconazole Dose Modification Guideline to Optimize Therapeutic Levels in Patients with Hematologic Malignancies
    Jeffrey Topal, MD ; Tiffany Lin, PharmD ; Sarah Perreault, PharmD ; Dayna Mcmanus, PharmD ; Michael Ruggero, PharmD

    CME Credits:

    ACPE Credits:

    ACPE Number:


    Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 7th with the exception of research findings presented at the IDWeek press conferences.